Fuertes Abardia C, Ballesta Juan P, Cruz Esteve I, Galindo Ortego G, Marsal Mora JR, Gomez-Arbones X. Potentially inappropriate prescribing: usefulness of STOPP/START criteria version 2 in Catalonian elderly population. Semergen. 2022 Apr;48(3):163-73. doi: 10.1016/j.semerg.2021.09.005
Montserrat-Capdevila J, Godoy P, Marsal JR, Ortega M, Pifarre J, Barbe F. Comorbidity in mental health in patients diagnosed with chronic obstructive pulmonary disease. Semergen. 2020 Jan;46(1):53-9. doi: 10.1016/j.semerg.2019.08.002
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.